1. Slaughter DP. The role of internal mammary node dissection in the treatment of breast cancer. Proc Inst Med Chic. 1953; 19:300.
2. Cheung DY, Kim TH, Kim CW, et al. The anatomical distribution of colorectal cancer in Korea: evaluation of the incidence of proximal and distal lesions and synchronous adenomas. Intern Med. 2008; 47:1649–1654. PMID:
18827411.
Article
3. Shin A, Hong CW, Sohn DK, et al. Associations of cigarette smoking and alcohol consumption with advanced or multiple colorectal adenoma risks: a colonoscopy-based case-control study in Korea. Am J Epidemiol. 2011; 174:552–562. PMID:
21791710.
Article
4. Jothy S, Slesak B, Harłozińska A, Lapińska J, Adamiak J, Rabczyński J. Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression. Tumour Biol. 1996; 17:58–64. PMID:
7501974.
Article
5. Chen LC, Hao CY, Chiu YS, et al. Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res. 2004; 64:3694–3700. PMID:
15150130.
Article
6. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005; 97:1330–1338. PMID:
16174854.
Article
7. Müller-Decker K, Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007; 46:705–710. PMID:
17546626.
Article
8. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005; 310:1504–1510. PMID:
16293724.
Article
9. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005; 65:1822–1829. PMID:
15753380.
Article
10. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2:544–551. PMID:
11905709.
Article
11. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107:1183–1188. PMID:
7926468.
Article
12. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006; 103:12098–12102. PMID:
16880406.
Article
13. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005; 280:3217–3223. PMID:
15542609.
Article
14. Lee HJ, Yang DH, Ryu YM, et al. 15-Hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms. J Korean Med Sci. 2013; 28:1154–1160. PMID:
23960441.
Article
15. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002; 68-69:483–493. PMID:
12432938.
Article
16. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A. 2004; 101:17468–17473. PMID:
15574495.
Article
17. Ryu YM, Myung SJ, Park YS, et al. Inhibition of 15-hydroxyprostaglandin dehydrogenase by Helicobacter pylori in human gastric carcinogenesis. Cancer Prev Res (Phila). 2013; 6:349–359. PMID:
23430757.
Article
18. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res. 2001; 7:3971–3976. PMID:
11751489.